nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP1A2—Imiquimod—skin cancer	0.181	0.295	CbGbCtD
Methotrimeprazine—CYP2E1—Dacarbazine—skin cancer	0.131	0.214	CbGbCtD
Methotrimeprazine—CYP1A2—Vemurafenib—skin cancer	0.0991	0.162	CbGbCtD
Methotrimeprazine—CYP2D6—Vemurafenib—skin cancer	0.0816	0.133	CbGbCtD
Methotrimeprazine—CYP1A2—Dacarbazine—skin cancer	0.0759	0.124	CbGbCtD
Methotrimeprazine—CYP1A2—Fluorouracil—skin cancer	0.0445	0.0726	CbGbCtD
Methotrimeprazine—DRD5—eyelid—skin cancer	0.0339	0.2	CbGeAlD
Methotrimeprazine—Necrotising enterocolitis neonatal—Docetaxel—skin cancer	0.0247	0.172	CcSEcCtD
Methotrimeprazine—Necrotizing enterocolitis—Docetaxel—skin cancer	0.0247	0.172	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Docetaxel—skin cancer	0.0202	0.141	CcSEcCtD
Methotrimeprazine—CHRM3—muscle of abdomen—skin cancer	0.0146	0.0859	CbGeAlD
Methotrimeprazine—HRH1—nose—skin cancer	0.0112	0.0664	CbGeAlD
Methotrimeprazine—CHRM5—skin epidermis—skin cancer	0.00951	0.0562	CbGeAlD
Methotrimeprazine—DRD1—nerve—skin cancer	0.0069	0.0408	CbGeAlD
Methotrimeprazine—Sudden death—Fluorouracil—skin cancer	0.00631	0.044	CcSEcCtD
Methotrimeprazine—Photosensitivity—Vemurafenib—skin cancer	0.00567	0.0395	CcSEcCtD
Methotrimeprazine—HTR2A—hindlimb—skin cancer	0.00442	0.0261	CbGeAlD
Methotrimeprazine—Liver injury—Temozolomide—skin cancer	0.00417	0.0291	CcSEcCtD
Methotrimeprazine—DRD2—nerve—skin cancer	0.00408	0.0241	CbGeAlD
Methotrimeprazine—Urinary retention—Imiquimod—skin cancer	0.00404	0.0282	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Vemurafenib—skin cancer	0.00393	0.0274	CcSEcCtD
Methotrimeprazine—HTR2A—appendage—skin cancer	0.0038	0.0224	CbGeAlD
Methotrimeprazine—Constipation—Vismodegib—skin cancer	0.00339	0.0236	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Imiquimod—skin cancer	0.00335	0.0234	CcSEcCtD
Methotrimeprazine—CHRM5—epithelium—skin cancer	0.0031	0.0183	CbGeAlD
Methotrimeprazine—CHRM5—skin of body—skin cancer	0.00295	0.0174	CbGeAlD
Methotrimeprazine—ADRA1D—epithelium—skin cancer	0.00277	0.0164	CbGeAlD
Methotrimeprazine—HTR2A—nerve—skin cancer	0.00269	0.0159	CbGeAlD
Methotrimeprazine—Photosensitivity—Fluorouracil—skin cancer	0.00267	0.0186	CcSEcCtD
Methotrimeprazine—DRD5—lymphoid tissue—skin cancer	0.00266	0.0157	CbGeAlD
Methotrimeprazine—DRD5—female reproductive system—skin cancer	0.00257	0.0152	CbGeAlD
Methotrimeprazine—Drug interaction—Docetaxel—skin cancer	0.00251	0.0175	CcSEcCtD
Methotrimeprazine—CHRM4—head—skin cancer	0.00246	0.0145	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Docetaxel—skin cancer	0.00233	0.0163	CcSEcCtD
Methotrimeprazine—HTR2A—endothelium—skin cancer	0.00229	0.0135	CbGeAlD
Methotrimeprazine—DRD3—head—skin cancer	0.00229	0.0135	CbGeAlD
Methotrimeprazine—ADRA2C—nipple—skin cancer	0.00225	0.0133	CbGeAlD
Methotrimeprazine—DRD5—head—skin cancer	0.00214	0.0127	CbGeAlD
Methotrimeprazine—HTR2A—blood vessel—skin cancer	0.00211	0.0125	CbGeAlD
Methotrimeprazine—Constipation—Vemurafenib—skin cancer	0.00209	0.0146	CcSEcCtD
Methotrimeprazine—ADRA1D—female reproductive system—skin cancer	0.00206	0.0122	CbGeAlD
Methotrimeprazine—Tachycardia—Imiquimod—skin cancer	0.00204	0.0142	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Dactinomycin—skin cancer	0.00202	0.0141	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Temozolomide—skin cancer	0.00201	0.014	CcSEcCtD
Methotrimeprazine—Weight increased—Temozolomide—skin cancer	0.002	0.014	CcSEcCtD
Methotrimeprazine—CYP1A2—nipple—skin cancer	0.00195	0.0115	CbGeAlD
Methotrimeprazine—CHRM5—head—skin cancer	0.00192	0.0114	CbGeAlD
Methotrimeprazine—Somnolence—Imiquimod—skin cancer	0.00186	0.0129	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Fluorouracil—skin cancer	0.00185	0.0129	CcSEcCtD
Methotrimeprazine—HRH1—nipple—skin cancer	0.00183	0.0108	CbGeAlD
Methotrimeprazine—Hypersensitivity—Vemurafenib—skin cancer	0.0018	0.0126	CcSEcCtD
Methotrimeprazine—ADRA2A—nipple—skin cancer	0.0018	0.0106	CbGeAlD
Methotrimeprazine—ADRA1B—head—skin cancer	0.00176	0.0104	CbGeAlD
Methotrimeprazine—ADRA1D—head—skin cancer	0.00172	0.0102	CbGeAlD
Methotrimeprazine—Agranulocytosis—Fluorouracil—skin cancer	0.00169	0.0118	CcSEcCtD
Methotrimeprazine—DRD1—head—skin cancer	0.00164	0.00967	CbGeAlD
Methotrimeprazine—ADRA1A—epithelium—skin cancer	0.00159	0.00939	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Docetaxel—skin cancer	0.00155	0.0108	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Imiquimod—skin cancer	0.00154	0.0107	CcSEcCtD
Methotrimeprazine—HTR2C—female reproductive system—skin cancer	0.00152	0.00899	CbGeAlD
Methotrimeprazine—HTR2A—neck—skin cancer	0.00151	0.00893	CbGeAlD
Methotrimeprazine—CHRM1—female reproductive system—skin cancer	0.00144	0.00849	CbGeAlD
Methotrimeprazine—Weight increased—Docetaxel—skin cancer	0.00133	0.00928	CcSEcCtD
Methotrimeprazine—CHRM2—head—skin cancer	0.00132	0.0078	CbGeAlD
Methotrimeprazine—ADRA2C—mammalian vulva—skin cancer	0.00131	0.00776	CbGeAlD
Methotrimeprazine—HRH1—connective tissue—skin cancer	0.0013	0.00766	CbGeAlD
Methotrimeprazine—CHRM3—female reproductive system—skin cancer	0.00129	0.0076	CbGeAlD
Methotrimeprazine—ADRA2A—connective tissue—skin cancer	0.00127	0.00752	CbGeAlD
Methotrimeprazine—HTR2C—head—skin cancer	0.00127	0.00751	CbGeAlD
Methotrimeprazine—Jaundice—Docetaxel—skin cancer	0.00127	0.00887	CcSEcCtD
Methotrimeprazine—HRH1—epithelium—skin cancer	0.00123	0.00727	CbGeAlD
Methotrimeprazine—ADRA1A—lymphoid tissue—skin cancer	0.00123	0.00724	CbGeAlD
Methotrimeprazine—Agranulocytosis—Docetaxel—skin cancer	0.00122	0.00849	CcSEcCtD
Methotrimeprazine—CHRM1—head—skin cancer	0.0012	0.0071	CbGeAlD
Methotrimeprazine—Tachycardia—Fluorouracil—skin cancer	0.00113	0.00784	CcSEcCtD
Methotrimeprazine—Somnolence—Temozolomide—skin cancer	0.00111	0.00775	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Bleomycin—skin cancer	0.00109	0.00762	CcSEcCtD
Methotrimeprazine—HTR2A—connective tissue—skin cancer	0.00108	0.0064	CbGeAlD
Methotrimeprazine—CHRM3—head—skin cancer	0.00108	0.00635	CbGeAlD
Methotrimeprazine—Constipation—Temozolomide—skin cancer	0.00107	0.00746	CcSEcCtD
Methotrimeprazine—HRH1—mammalian vulva—skin cancer	0.00107	0.00631	CbGeAlD
Methotrimeprazine—ADRA2A—mammalian vulva—skin cancer	0.00105	0.0062	CbGeAlD
Methotrimeprazine—HTR2A—epithelium—skin cancer	0.00103	0.00607	CbGeAlD
Methotrimeprazine—Somnolence—Fluorouracil—skin cancer	0.00102	0.00714	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Dactinomycin—skin cancer	0.00102	0.00711	CcSEcCtD
Methotrimeprazine—ADRA1A—head—skin cancer	0.000987	0.00583	CbGeAlD
Methotrimeprazine—DRD2—head—skin cancer	0.000968	0.00571	CbGeAlD
Methotrimeprazine—ADRA2C—head—skin cancer	0.000941	0.00556	CbGeAlD
Methotrimeprazine—Hypersensitivity—Temozolomide—skin cancer	0.000922	0.00643	CcSEcCtD
Methotrimeprazine—HRH1—female reproductive system—skin cancer	0.000915	0.0054	CbGeAlD
Methotrimeprazine—CYP2E1—lymphoid tissue—skin cancer	0.000911	0.00538	CbGeAlD
Methotrimeprazine—ADRA2A—female reproductive system—skin cancer	0.000898	0.00531	CbGeAlD
Methotrimeprazine—CYP2E1—female reproductive system—skin cancer	0.000879	0.00519	CbGeAlD
Methotrimeprazine—Hypersensitivity—Fluorouracil—skin cancer	0.000849	0.00592	CcSEcCtD
Methotrimeprazine—Tachycardia—Docetaxel—skin cancer	0.000812	0.00566	CcSEcCtD
Methotrimeprazine—HRH1—head—skin cancer	0.000764	0.00451	CbGeAlD
Methotrimeprazine—HTR2A—female reproductive system—skin cancer	0.000764	0.00451	CbGeAlD
Methotrimeprazine—ADRA2A—head—skin cancer	0.000751	0.00443	CbGeAlD
Methotrimeprazine—Somnolence—Docetaxel—skin cancer	0.00074	0.00516	CcSEcCtD
Methotrimeprazine—CYP2E1—head—skin cancer	0.000734	0.00434	CbGeAlD
Methotrimeprazine—Constipation—Docetaxel—skin cancer	0.000712	0.00496	CcSEcCtD
Methotrimeprazine—CYP2D6—female reproductive system—skin cancer	0.000696	0.00411	CbGeAlD
Methotrimeprazine—ADRA2C—lymph node—skin cancer	0.000659	0.00389	CbGeAlD
Methotrimeprazine—HTR2A—head—skin cancer	0.000638	0.00377	CbGeAlD
Methotrimeprazine—Hypersensitivity—Docetaxel—skin cancer	0.000613	0.00427	CcSEcCtD
Methotrimeprazine—CYP2D6—head—skin cancer	0.000581	0.00343	CbGeAlD
Methotrimeprazine—HRH1—lymph node—skin cancer	0.000535	0.00316	CbGeAlD
Methotrimeprazine—ADRA2A—lymph node—skin cancer	0.000526	0.0031	CbGeAlD
Methotrimeprazine—ADRA2A—Signaling Pathways—SHH—skin cancer	2.85e-05	0.000385	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTGER4—skin cancer	2.84e-05	0.000384	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—RASA1—skin cancer	2.83e-05	0.000383	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	2.83e-05	0.000383	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—FOXO4—skin cancer	2.82e-05	0.000381	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—NRAS—skin cancer	2.81e-05	0.000379	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CSPG4—skin cancer	2.77e-05	0.000374	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—BRAF—skin cancer	2.74e-05	0.00037	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	2.7e-05	0.000365	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SMO—skin cancer	2.7e-05	0.000365	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	2.63e-05	0.000356	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—FOXO4—skin cancer	2.6e-05	0.000351	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Hemostasis—KRAS—skin cancer	2.58e-05	0.000349	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—FOXO4—skin cancer	2.55e-05	0.000345	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TERT—skin cancer	2.55e-05	0.000345	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—FOXO4—skin cancer	2.55e-05	0.000344	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—FOXO4—skin cancer	2.54e-05	0.000343	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—FOXO4—skin cancer	2.53e-05	0.000342	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TERT—skin cancer	2.52e-05	0.00034	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—FOXO4—skin cancer	2.51e-05	0.000339	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—KRAS—skin cancer	2.51e-05	0.000339	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	2.5e-05	0.000338	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—ERCC2—skin cancer	2.44e-05	0.00033	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—KRAS—skin cancer	2.41e-05	0.000326	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TERT—skin cancer	2.41e-05	0.000326	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	2.32e-05	0.000314	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Hemostasis—TP53—skin cancer	2.3e-05	0.000311	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TERT—skin cancer	2.3e-05	0.00031	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—NRAS—skin cancer	2.28e-05	0.000308	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TERT—skin cancer	2.27e-05	0.000306	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TERT—skin cancer	2.27e-05	0.000306	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ENO2—skin cancer	2.22e-05	0.0003	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Hemostasis—HRAS—skin cancer	2.2e-05	0.000297	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—ERCC2—skin cancer	2.16e-05	0.000292	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—NRAS—skin cancer	2.15e-05	0.00029	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—TP53—skin cancer	2.15e-05	0.00029	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—HRAS—skin cancer	2.13e-05	0.000288	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—NRAS—skin cancer	2.12e-05	0.000287	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—HRAS—skin cancer	2.05e-05	0.000277	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TERT—skin cancer	2.05e-05	0.000276	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—IL6—skin cancer	2.04e-05	0.000276	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—NRAS—skin cancer	2.03e-05	0.000274	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—BRAF—skin cancer	2.02e-05	0.000273	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—BRAF—skin cancer	1.99e-05	0.000269	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—ERCC2—skin cancer	1.98e-05	0.000268	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TERT—skin cancer	1.96e-05	0.000266	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—KRAS—skin cancer	1.96e-05	0.000265	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—NRAS—skin cancer	1.93e-05	0.000262	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TERT—skin cancer	1.91e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—NRAS—skin cancer	1.91e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.91e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—BRAF—skin cancer	1.91e-05	0.000258	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ENO2—skin cancer	1.88e-05	0.000254	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TERT—skin cancer	1.88e-05	0.000254	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—KRAS—skin cancer	1.85e-05	0.00025	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—KRAS—skin cancer	1.82e-05	0.000247	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—BRAF—skin cancer	1.82e-05	0.000246	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—ERCC2—skin cancer	1.82e-05	0.000246	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.79e-05	0.000243	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—BRAF—skin cancer	1.79e-05	0.000243	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—KRAS—skin cancer	1.75e-05	0.000236	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—TP53—skin cancer	1.74e-05	0.000236	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TERT—skin cancer	1.73e-05	0.000234	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.72e-05	0.000233	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—NRAS—skin cancer	1.72e-05	0.000233	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TERT—skin cancer	1.71e-05	0.000231	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TERT—skin cancer	1.7e-05	0.00023	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TERT—skin cancer	1.7e-05	0.000229	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TERT—skin cancer	1.69e-05	0.000229	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TERT—skin cancer	1.68e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TERT—skin cancer	1.67e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—HRAS—skin cancer	1.67e-05	0.000225	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—KRAS—skin cancer	1.67e-05	0.000225	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.66e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—KRAS—skin cancer	1.64e-05	0.000222	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	1.64e-05	0.000222	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.62e-05	0.000219	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.61e-05	0.000218	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1.58e-05	0.000214	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—HRAS—skin cancer	1.57e-05	0.000213	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—BRAF—skin cancer	1.56e-05	0.00021	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TERT—skin cancer	1.55e-05	0.00021	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—HRAS—skin cancer	1.55e-05	0.00021	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.51e-05	0.000205	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—IL6—skin cancer	1.5e-05	0.000203	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.49e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—HRAS—skin cancer	1.49e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—IL6—skin cancer	1.48e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.48e-05	0.0002	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—KRAS—skin cancer	1.48e-05	0.0002	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.47e-05	0.000199	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PTGS2—skin cancer	1.46e-05	0.000198	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—NRAS—skin cancer	1.46e-05	0.000197	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.44e-05	0.000194	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—NRAS—skin cancer	1.43e-05	0.000194	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—NRAS—skin cancer	1.43e-05	0.000193	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—NRAS—skin cancer	1.43e-05	0.000193	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.42e-05	0.000193	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—IL6—skin cancer	1.42e-05	0.000192	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—HRAS—skin cancer	1.42e-05	0.000191	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—NRAS—skin cancer	1.41e-05	0.000191	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1.41e-05	0.00019	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—HRAS—skin cancer	1.4e-05	0.000189	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	1.4e-05	0.000189	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.39e-05	0.000187	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—BRAF—skin cancer	1.37e-05	0.000186	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	1.36e-05	0.000184	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—IL6—skin cancer	1.35e-05	0.000183	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—BRAF—skin cancer	1.35e-05	0.000183	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—BRAF—skin cancer	1.35e-05	0.000182	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—BRAF—skin cancer	1.34e-05	0.000182	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—BRAF—skin cancer	1.34e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—IL6—skin cancer	1.34e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—IL6—skin cancer	1.34e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—BRAF—skin cancer	1.33e-05	0.000179	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—BRAF—skin cancer	1.32e-05	0.000179	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—TP53—skin cancer	1.32e-05	0.000178	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.31e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PTGS2—skin cancer	1.29e-05	0.000175	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ERCC2—skin cancer	1.29e-05	0.000174	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—NRAS—skin cancer	1.27e-05	0.000172	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.26e-05	0.00017	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—HRAS—skin cancer	1.26e-05	0.00017	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—KRAS—skin cancer	1.26e-05	0.00017	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—NRAS—skin cancer	1.25e-05	0.000169	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.24e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—KRAS—skin cancer	1.23e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—KRAS—skin cancer	1.23e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.23e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—KRAS—skin cancer	1.23e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—KRAS—skin cancer	1.21e-05	0.000164	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	1.21e-05	0.000164	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.21e-05	0.000164	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.21e-05	0.000163	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL6—skin cancer	1.2e-05	0.000163	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—NRAS—skin cancer	1.2e-05	0.000162	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PTGS2—skin cancer	1.19e-05	0.00016	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.18e-05	0.000159	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	1.16e-05	0.000157	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL6—skin cancer	1.16e-05	0.000157	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—NRAS—skin cancer	1.14e-05	0.000154	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—NRAS—skin cancer	1.13e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—NRAS—skin cancer	1.13e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL6—skin cancer	1.13e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	1.13e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL6—skin cancer	1.11e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ERCC2—skin cancer	1.09e-05	0.000148	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—KRAS—skin cancer	1.09e-05	0.000148	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTGS2—skin cancer	1.09e-05	0.000147	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—KRAS—skin cancer	1.08e-05	0.000146	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—HRAS—skin cancer	1.07e-05	0.000144	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—HRAS—skin cancer	1.05e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—HRAS—skin cancer	1.05e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—HRAS—skin cancer	1.05e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—HRAS—skin cancer	1.04e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—HRAS—skin cancer	1.03e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—KRAS—skin cancer	1.03e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	1.03e-05	0.000139	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL6—skin cancer	1.02e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—NRAS—skin cancer	1.02e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL6—skin cancer	1.01e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL6—skin cancer	1e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL6—skin cancer	1e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL6—skin cancer	9.98e-06	0.000135	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL6—skin cancer	9.88e-06	0.000134	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL6—skin cancer	9.85e-06	0.000133	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—KRAS—skin cancer	9.84e-06	0.000133	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—NRAS—skin cancer	9.78e-06	0.000132	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TP53—skin cancer	9.71e-06	0.000131	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—KRAS—skin cancer	9.71e-06	0.000131	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—KRAS—skin cancer	9.71e-06	0.000131	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—skin cancer	9.58e-06	0.000129	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	9.57e-06	0.000129	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NRAS—skin cancer	9.51e-06	0.000129	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NRAS—skin cancer	9.36e-06	0.000127	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HRAS—skin cancer	9.29e-06	0.000126	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—skin cancer	9.18e-06	0.000124	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HRAS—skin cancer	9.16e-06	0.000124	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—skin cancer	9.16e-06	0.000124	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—skin cancer	8.89e-06	0.00012	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HRAS—skin cancer	8.78e-06	0.000119	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—skin cancer	8.77e-06	0.000119	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—skin cancer	8.76e-06	0.000118	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—skin cancer	8.74e-06	0.000118	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NRAS—skin cancer	8.63e-06	0.000117	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—skin cancer	8.63e-06	0.000117	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—skin cancer	8.63e-06	0.000117	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NRAS—skin cancer	8.49e-06	0.000115	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NRAS—skin cancer	8.47e-06	0.000115	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NRAS—skin cancer	8.45e-06	0.000114	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NRAS—skin cancer	8.42e-06	0.000114	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—skin cancer	8.42e-06	0.000114	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—skin cancer	8.4e-06	0.000114	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HRAS—skin cancer	8.36e-06	0.000113	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NRAS—skin cancer	8.34e-06	0.000113	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NRAS—skin cancer	8.31e-06	0.000112	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HRAS—skin cancer	8.25e-06	0.000112	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HRAS—skin cancer	8.25e-06	0.000112	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—skin cancer	8.19e-06	0.000111	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—skin cancer	8.06e-06	0.000109	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—skin cancer	8e-06	0.000108	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—skin cancer	7.9e-06	0.000107	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—skin cancer	7.9e-06	0.000107	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—skin cancer	7.79e-06	0.000105	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTGS2—skin cancer	7.74e-06	0.000105	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NRAS—skin cancer	7.73e-06	0.000104	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—skin cancer	7.48e-06	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRAS—skin cancer	7.45e-06	0.000101	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—skin cancer	7.43e-06	0.0001	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—skin cancer	7.31e-06	9.88e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—skin cancer	7.29e-06	9.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—skin cancer	7.28e-06	9.83e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—skin cancer	7.27e-06	9.82e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—skin cancer	7.25e-06	9.79e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—skin cancer	7.18e-06	9.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—skin cancer	7.16e-06	9.68e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—skin cancer	7.16e-06	9.67e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRAS—skin cancer	7.15e-06	9.67e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—skin cancer	7.13e-06	9.64e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRAS—skin cancer	6.96e-06	9.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRAS—skin cancer	6.85e-06	9.26e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—skin cancer	6.85e-06	9.25e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—skin cancer	6.66e-06	9e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—skin cancer	6.65e-06	8.99e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—skin cancer	6.6e-06	8.92e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTGS2—skin cancer	6.55e-06	8.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—skin cancer	6.55e-06	8.86e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—skin cancer	6.5e-06	8.78e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—skin cancer	6.48e-06	8.76e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—skin cancer	6.46e-06	8.73e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—skin cancer	6.44e-06	8.7e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—skin cancer	6.38e-06	8.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—skin cancer	6.36e-06	8.6e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRAS—skin cancer	6.31e-06	8.53e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRAS—skin cancer	6.21e-06	8.4e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRAS—skin cancer	6.2e-06	8.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRAS—skin cancer	6.18e-06	8.35e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRAS—skin cancer	6.16e-06	8.32e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRAS—skin cancer	6.1e-06	8.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRAS—skin cancer	6.08e-06	8.22e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—skin cancer	6.04e-06	8.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—skin cancer	5.95e-06	8.04e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—skin cancer	5.93e-06	8.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—skin cancer	5.91e-06	7.99e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—skin cancer	5.91e-06	7.99e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—skin cancer	5.89e-06	7.97e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—skin cancer	5.84e-06	7.89e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—skin cancer	5.82e-06	7.87e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRAS—skin cancer	5.65e-06	7.64e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—skin cancer	5.41e-06	7.31e-05	CbGpPWpGaD
